600645.SHG Vcanbio Cell & Gene Engineering Corp Ltd
- Market cap
- CNY 8.35B
- P/E
- 74.4x
- P/B
- 2.11x
- ROE
- 3.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600645.SHG undervalued?
Graham number600645.SHG trades 163.9% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Vcanbio Cell & Gene Engineering Corp Ltd fundamental analysis
No fundamental analysis for Vcanbio Cell & Gene Engineering Corp Ltd yet.
Vcanbio Cell & Gene Engineering Corp Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Vcanbio Cell & Gene Engineering Corp Ltd
Vcanbio Cell & Gene Engineering Corp., Ltd, together with its subsidiaries, engages in the preparation and storage of cell detection tests in the People's Republic of China. It offers cell test preparation and storage services for umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, immune cells, adipose stem cells and dental stem cells. The company also provides prenatal genetic testing for pregnancy, childr…
Full company profileVcanbio Cell & Gene Engineering Corp Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Vcanbio Cell & Gene Engineering Corp Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 838M | 1.32B | 1.32B | 1.39B | 1.32B | 1.54B | 1.55B | 1.59B | 1.59B | 1.45B | 1.35B |
| Gross Profit | 543M | 879M | 866M | 936M | 868M | 1.06B | 1.04B | 1.08B | 1.09B | 1.02B | 968M |
| Operating Income | 80.5M | 53.7M | 102M | 109M | -92.7M | 220M | 156M | 131M | 136M | 197M | 188M |
| EBITDA | 164M | 193M | 146M | 275M | 197M | 227M | 254M | 282M | 266M | 336M | 202M |
| Net Income | 37.9M | 10.4M | 59.3M | 49.7M | -127M | 155M | 113M | 106M | 100M | 114M | 142M |
| EPS | 0.10 | 0.03 | 0.15 | 0.11 | -0.27 | 0.33 | 0.24 | 0.23 | 0.22 | 0.24 | 0.30 |
| Balance Sheet | |||||||||||
| Total Assets | 3.00B | 3.00B | 4.44B | 4.89B | 4.88B | 5.03B | 5.28B | 5.41B | 5.25B | 5.29B | 5.35B |
| Total Liabilities | 1.25B | 1.37B | 1.46B | 1.43B | 1.38B | 1.50B | 1.63B | 1.61B | 1.59B | 1.54B | 1.49B |
| Shareholders' Equity | 1.59B | 1.51B | 2.77B | 3.35B | 3.42B | 3.46B | 3.56B | 3.68B | 3.60B | 3.71B | 3.82B |
| Cash & Short-term Investments | 413M | 253M | 585M | 1.03B | 1.06B | 1.20B | 1.39B | 1.58B | 1.52B | 1.01B | 1.23B |
| Total Debt | 118M | 179M | 195M | 136M | 110M | 87.3M | 130M | 116M | 68.4M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 144M | 70.3M | 130M | 241M | 244M | 321M | 262M | 299M | 285M | 314M | - |
| Capital Expenditure | 270M | 83.0M | 128M | 123M | 91.7M | 128M | 99.2M | 88.6M | 67.3M | 49.6M | 38.7M |
| Free Cash Flow | -126M | -12.7M | 1.95M | 119M | 153M | 193M | 163M | 210M | 218M | 264M | 231M |
| Ratios | |||||||||||
| ROE | 2.4% | 0.7% | 2.1% | 1.5% | -3.7% | 4.5% | 3.2% | 2.9% | 2.8% | 3.1% | 3.7% |
| ROA | 1.3% | 0.3% | 1.3% | 1.0% | -2.6% | 3.1% | 2.1% | 2.0% | 1.9% | 2.2% | 2.7% |
| Net Profit Margin | 4.5% | 0.8% | 4.5% | 3.6% | -9.6% | 10.1% | 7.3% | 6.7% | 6.3% | 7.8% | 10.5% |
| Debt to Equity | 0.07x | 0.12x | 0.07x | 0.04x | 0.03x | 0.03x | 0.04x | 0.03x | 0.02x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Vcanbio Cell & Gene Engineering Corp Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Aug 10, 2001
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | CNY 591K | 0.00 | 0.6% |
| 2023 | CNY 917K | 0.00 | 0.9% |
| 2022 | CNY 1.27M | 0.00 | 1.1% |
| 2021 | CNY 1.61M | 0.00 | 1.0% |
| 2020 | CNY 4.02M | 0.01 | - |
| 2019 | CNY 11.3M | 0.03 | 22.8% |
| 2018 | CNY 11.7M | 0.03 | 19.7% |
| 2017 | CNY 11.6M | 0.03 | 112.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 16.983:10 on Jan 24, 2007.
Who owns Vcanbio Cell & Gene Engineering Corp Ltd
- Insiders 29.32%
- Institutions 6.05%
- Public & others 64.63%
- Shares outstanding 468M
- Free float 341M
Vcanbio Cell & Gene Engineering Corp Ltd company profile
- Company name
- Vcanbio Cell & Gene Engineering Corp Ltd
- Ticker
- 600645.SHG
- ISIN
- CNE000000545
- Exchange
- Shanghai Stock Exchange
- Listed since
- Aug 18, 1992
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,935
- Fiscal year end
- December
- Address
- Huayuan Industrial Zone, Tianjin, China, 300384
- Phone
- 86 22 5877 5766
- Website
- vcanbio.com
About Vcanbio Cell & Gene Engineering Corp Ltd
Vcanbio Cell & Gene Engineering Corp., Ltd, together with its subsidiaries, engages in the preparation and storage of cell detection tests in the People's Republic of China. It offers cell test preparation and storage services for umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, immune cells, adipose stem cells and dental stem cells. The company also provides prenatal genetic testing for pregnancy, children and adults, disease inheritance, and disease susceptibility; and in vitro diagnostic raw materials such as monoclonal antibodies and polyclonal antibody products, and the research, development, production and sales of Class I, Class II and Class III in vitro diagnostic reagents and medical devices. In addition, it is involved in the research, development, production, and sales of biological genes, proteins, antibodies, and pharmaceutical intermediates. The company was founded in 1992 and is based in Tianjin, the People's Republic of China.
Vcanbio Cell & Gene Engineering Corp Ltd management
7- Mr. Hongqi WangVice Chairman & GM · born 1964
- Mr. Yu ZhangCo- President & Director · born 1985
- Mr. Hong Xiang ShiDeputy General Manager · born 1983
- Mr. Yang FanChief Financial Officer · born 1972
- Lu LiAccounting Supervisor
- Dr. Huang JiaxueChief Technical Quality Officer
- Mr. Yueming WangChief Human Resources Officer